Drug Development & CDMO Survey Please select the primary focus of your drug development pipeline. 50% Small Molecule American Pharmaceutical Review recently conducted a survey of our readers to determine their thoughts regarding Drug Development & CDMOs. Please see the results of our survey below. Please rank the key factors when selecting a CDMO. (1 - most important; 5 - least important) 24.14% 27.59% Technology 13.79% 10.34% 51.72% Quality 3.45% 3.45% 10.34% Price 10.34% 3.45% 0% Flexibility 6.9% 41.38% 48.28% 10.34% 27.59% Experience 10.34% 27.59% What is your current drug development need? Scale-up 51.72% 37.93% Formulation development 34.48% Formulation optimization 31.03% cGMP clinical trial material supply 17.24% Commercial manufacturing 12.5% CNS 3.45% Tox supply 9.38% Other What disease area(s) will your next project to focus on? 46.88% Inflammatory/Immune 28.13% Oncology 28.13% Infectious diseases 21.88% Endocrine/Metabolism 24.14% What is your biggest hurdle in drug development? Schedule/Timeline Cost/Budget 28.13% 25.00% Formulation development 21.88% Regulatory Other 3.13% 21.88% 24.14% 24.14% 31.03% 20.69% 20.69% 24.14% 1 2 3 4 5 8.82% Protein 14.71% Antibody 17.65% Cell/Gene Therapy 5.88% Peptide 2.94% Other What kind of dosage types do you work with? 50% Oral 9.38% Ocular 28.13% Parenteral 25% Topical 37.5% Injectable 12.5% Nasal 12.5% Other